American Tegumentary Leishmaniasis: Is Antimonial Treatment Outcome Related to Parasite Drug Susceptibility? | Zendy

Vanessa Yardley | Zendy; Nimer Ortuño | Zendy; Alejandro LlanosCuentas | Zendy; François Chappuis | Zendy; Simonne De Doncker | Zendy; Luı́s Eduardo Ramı́rez | Zendy; Simon L. Croft | Zendy; Jorge Arévalo | Zendy; Vanessa Adaui | Zendy; Hernán Bermúdez | Zendy; Saskia Decuypere | Zendy; JeanClaude Dujardin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

American Tegumentary Leishmaniasis: Is Antimonial Treatment Outcome Related to Parasite Drug Susceptibility?

Author(s) -

Vanessa Yardley,

Nimer Ortuño,

Alejandro LlanosCuentas,

François Chappuis,

Simonne De Doncker,

Luı́s Eduardo Ramı́rez,

Simon L. Croft,

Jorge Arévalo,

Vanessa Adaui,

Hernán Bermúdez,

Saskia Decuypere,

JeanClaude Dujardin

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/507710

Subject(s) - amastigote , leishmaniasis , drug resistance , parasite hosting , drug , sodium stibogluconate , biology , leishmania , in vitro , medicine , immunology , cutaneous leishmaniasis , pharmacology , microbiology and biotechnology , biochemistry , world wide web , computer science

Antimonials are the first drug of choice for the treatment of American tegumentary leishmaniasis (ATL); however, their efficacy is not predictable, and this may be linked to parasite drug resistance. We aimed to characterize the in vitro antimony susceptibility of clinical isolates of Peruvian patients with ATL who were treated with sodium stibogluconate and to correlate this in vitro phenotype with different treatment outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research